Barclays PLC Incyte Corp Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Incyte Corp stock. As of the latest transaction made, Barclays PLC holds 1,031,932 shares of INCY stock, worth $72.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,031,932

Previous 1,031,932 -0.0%

Holding current value

$72.8 Million

Previous $68.2 Million -0.0%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$57.33 - $68.61 $7.89 Million - $9.44 Million	137,542 Added 15.38%	1,031,932 $68.2 Million
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $20.5 Million - $25.6 Million	401,045 Added 81.29%	894,390 $54.2 Million
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $311,138 - $366,378	5,502 Added 1.13%	493,345 $28.1 Million
Q4 2023 Feb 15, 2024	BUY	$52.16 - $64.19 $4 Million - $4.92 Million	76,703 Added 18.66%	487,843 $30.6 Million
Q3 2023 Nov 07, 2023	BUY	$57.77 - $65.93 $21,548 - $24,591	373 Added 0.09%	411,140 $23.8 Million
Q2 2023 Aug 03, 2023	SELL	$60.95 - $75.51 $3.32 Million - $4.12 Million	-54,510 Reduced 11.72%	410,767 $25.6 Million
Q1 2023 May 04, 2023	BUY	$70.23 - $86.01 $3.09 Million - $3.78 Million	43,961 Added 10.43%	465,277 $33.6 Million
Q4 2022 Feb 13, 2023	SELL	$67.18 - $84.11 $91.8 Million - $115 Million	-1,365,979 Reduced 76.43%	421,316 $33.8 Million
Q3 2022 Nov 03, 2022	BUY	$66.18 - $82.86 $78.5 Million - $98.2 Million	1,185,627 Added 197.06%	1,787,295 $119 Million
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $24.2 Million - $30.4 Million	365,161 Added 154.4%	601,668 $45.7 Million
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $8.1 Million - $9.78 Million	-122,713 Reduced 34.16%	236,507 $18.8 Million
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $2.1 Million - $2.46 Million	-33,137 Reduced 8.45%	359,220 $26.4 Million
Q3 2021 Nov 09, 2021	BUY	$68.67 - $84.02 $6.35 Million - $7.77 Million	92,437 Added 30.82%	392,357 $27 Million
Q2 2021 Aug 13, 2021	BUY	$79.87 - $87.53 $2.46 Million - $2.7 Million	30,860 Added 11.47%	299,920 $25.2 Million
Q1 2021 May 13, 2021	BUY	$76.02 - $100.5 $3.52 Million - $4.66 Million	46,359 Added 20.82%	269,060 $21.9 Million
Q4 2020 Feb 11, 2021	BUY	$80.74 - $97.7 $3.25 Million - $3.93 Million	40,209 Added 22.03%	222,701 $19.4 Million
Q3 2020 Nov 12, 2020	BUY	$85.07 - $109.69 $2.77 Million - $3.58 Million	32,601 Added 21.75%	182,492 $16.4 Million
Q2 2020 Aug 12, 2020	SELL	$74.18 - $108.93 $589,063 - $865,013	-7,941 Reduced 5.03%	149,891 $15.6 Million
Q1 2020 May 13, 2020	SELL	$63.18 - $85.97 $21.3 Million - $29.1 Million	-337,910 Reduced 68.16%	157,832 $11.6 Million
Q4 2019 Feb 10, 2020	BUY	$73.04 - $95.72 $3.16 Million - $4.14 Million	43,216 Added 9.55%	495,742 $43.3 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $6 Million - $7.13 Million	82,402 Added 22.26%	452,526 $33.6 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $8.71 Million - $10.5 Million	118,457 Added 47.07%	370,124 $31.4 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $9.03 Million - $12.5 Million	-142,137 Reduced 36.09%	251,667 $21.6 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $19,246 - $23,010	329 Added 0.08%	393,804 $25 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $3.94 Million - $4.74 Million	63,806 Added 19.35%	393,475 $27.2 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $15.5 Million - $21.4 Million	-254,944 Reduced 43.61%	329,669 $22.1 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $815,566 - $991,522	9,819 Added 1.71%	584,613 $48.7 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $10.1 Million - $12.6 Million	107,797 Added 23.08%	574,794 $54.4 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $51 Million - $64.6 Million	466,997	466,997 $54.5 Million

Others Institutions Holding INCY

# of Institutions

645

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account